Skip to main content

Wilson's Disease News

FDA Approves Cuvrior (trientine tetrahydrochloride) for the Treatment of Wilson’s disease

Paris, France 2 May 2022 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialisation company, today announces approval of Cuvrior™, a new salt of trient...

Ask a question

To post your own question to this support group, sign in or create an account.